ARS Pharma
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
11682 El Camino Real Ste 300, San Diego,...Phone Number
(858) 771-9307Website
www.ars-pharma.comRevenue
$99 MillionStock Symbol
SPRYIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About ARS Pharma
ARS Pharm operates as a pharmaceutical company. The Company develops an intranasal epinephrine spray with a unique absorption technology to save patients from allergic reactions of food, medications, and insect bites. Established in 2015, ARS Pharm is headquartered in San Diego, California, United States.Explore more
ARS Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ARS Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once ARS Pharma has new funding data
Product Launch: Get notified when ARS Pharma launches new products
Congratulate Masked Content for being promoted to Masked Content at ARS Pharma
ARS Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if ARS Pharma is spiking on competitors!
Earning: See what the market has to say on ARS Pharma recently announced quarterly report
Click to see if ARS Pharma had a recent Job posting/layoffs
Check if ARS Pharma has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at ARS Pharma
Find 3 more new buyers
Compare Similar Companies to ARS Pharma
Compare insights from companies similar to ARS Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
ARS Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
ARS Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about ARS Pharma.
ARS Pharma financials insights
Gather financial insights about ARS Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series C
$20M
2021
Series D
$55M
ARS Pharma Tech Stack
A closer look at the technologies used by ARS Pharma
Most Recent Scoops
Open Position
Earnings
ended Q2 with $143.8 million in cash equivalents and short-term investments, and anticipates reaching cash flow breakeven by the end of 2027.
Accounting, Forecasting, Financial Reporting, Business Finance, Finance
Earnings
ARS Pharma has adjusted its aggregate SG&A and R&D expenses for H2 2026 to a range of $114 million to $126 million, including approximately $14 million to $16 million in stock-based compensation, with total cash-based SG&A and R&D expenses expected in the range of $100 million to $110 million, reflecting a more than 40% reduction in cash-based SG&A from H1 2026.
Earnings, Spending/Investment, Finance
Earnings
ARS Pharma has reported total revenue of $33.7 million for Q2, with total operating expenses of $95.1 million, including $12.8 million in cost of goods sold and $77.6 million in SG&A expenses.
Earnings, Finance
Earnings
Earnings, Finance
ARS Pharma News & Media
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm
New class action for ARS (SPRY) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 10/5/2026Kaplan Fox Reminds ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors with Significant Losses to Seek a Leadership Role Before Deadline on October 5, 2026
Kaplan Fox announces a securities class action against ARS Pharmaceuticals (NASDAQ: SPRY) for investors from March 9, 2026 to June 24, 2026.SPRY Deadline Alert: SueWallSt Reminds ARS Pharmaceuticals Inc. (SPRY) Investors of Securities Class Action Deadline on October 5, 2026
A securities class action alleges ARS Pharmaceuticals paired specific, confident statements about a July 1, 2026 CVS Caremark formulary date with only generalized risk language, leaving SPRY investors exposed to a 23.9% single-day decline.SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
LOS ANGELES, Sept. 22, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ: SPRY) for violations of §§10(b) and 20(a) of the...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ARS Pharma
Sign Up For FreeTo access detailed company insights
ARS Pharm operates as a pharmaceutical company. The Company develops an intranasal epinephrine spray with a unique absorption technology to save patients from allergic reactions of food, medications, and insect bites. Established in 2015, ARS Pharm is headquartered in San Diego, California, United States.... Read More
